<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-9906-2016011 - 2S4KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">RNA helicase DDX3 is a novel sensor for HIV-1</narrative>
  </title>
  <description type="4">
   <narrative xml:lang="EN">Here we aim to identify novel strategies to enhance innate antiviral immunity to HIV-1 to limit establishment and progression of chronic disease. Dendritic cells (DCs) and macrophages are paramount in inducing antiviral immunity. However, current paradigm suggests that DCs do not induce effective antiviral immune responses to HIV-1, because HIV-1 evades or suppresses innate sensing mechanisms in DCs [1]. Therefore, an intense research effort in the field is being undertaken to identify HIV-1 sensors and to understand how HIV-1 escapes innate immunity. Recent focus of the field has been primarily on DNA sensors for HIV-1 such as cyclic GMP-AMP synthase (cGAS) and IFIT16 [2-3]. These sensors sense HIV-1 RT DNA and activate transcription factor IRF3 via STING to drive type I Interferon (IFN-I) expression. IFN-I responses are crucial in mounting antiviral innate responses limiting HIV-1 replication, not only in DC subsets but also in macrophages, as well as inducing DC maturation for induction of adaptive immunity. Strikingly, we have suggestions that novel data show that DDX3 is a novel RNA sensor in myeloid, skin, vaginal and rectal DCs, but that this sensing mechanism is inhibited by HIV-1 via DC-SIGN signaling. Here we will build on our exciting data to further investigate the importance of this RNA sensor in HIV-1 infection of different DC subsets and macrophages, and how its function can be harnessed to induce antiviral immunity.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">Here we will identify the importance of RNA sensor DDX3 in HIV-1 infection, elucidate HIV-1 escape mechanisms and develop innovative therapies to boost immunity to HIV-1 and limit HIV-1 in acute and chronic HIV-1 infection. 

Outcomes: We will identify novel innovative therapies to boost immunity or even prevent establishment and progression to chronic HIV-1 disease by antagonizing HIV-1 suppression of innate sensing.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">Immune dysfunction is a major problem in HIV-1-infected patients causing co-morbidities. Innate sensing of HIV-1 is crucial for induction of innate and adaptive immunity. However, HIV-1 evades or blocks innate sensing in immune cells, which prevents effective immunity to HIV-1 and might underlie the observed immune dysfunction. We have recently identified the RNA helicase DDX3 as a novel sensor for HIV-1 in dendritic cells. Strikingly, our novel data demonstrate that HIV-1 actively suppresses DDX3 function and antagonizing this HIV-1 suppression by inhibitors strongly enhanced antiviral immunity. Here we will identify the function of the RNA sensor DDX3 in dendritic cell subsets and macrophages, and investigate how we can target this sensor to enhance antiviral immunity to HIV-1. Remarkably, we identified a dual polymorphism in MAVS, a component of the novel HIV-1 sensing machinery, rendering the pathway insensitive to HIV-1 suppression in both dendritic cells and macrophages. Strikingly, this polymorphism is associated with lower viral replication in HIV-1-infected patients from the Amsterdam Cohort Studies for HIV-1/AIDS. Thus, preventing HIV-1 from blocking this novel RNA sensing mechanism will enhance antiviral immunity, limiting HIV-1 replication and potentially restore immune function in infected patients.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">scientific communitty</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2017-01-01" type="2"></activity-date>
  <activity-date iso-date="2021-01-01" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
   </organisation>
   <email>IATI@aidsfonds.nl</email>
   <website>https://aidsfonds.nl/</website>
   <mailing-address>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland, Condensatorweg 54, 1014 AX Amsterdam</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="50" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <sector code="16064" percentage="50" vocabulary="1">
   <narrative xml:lang="EN">Social mitigation of HIV/AIDS</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C58" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2021-01-01"></period-end>
   <value currency="EUR" value-date="2017-01-01">264470</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-11-28"></transaction-date>
   <value currency="EUR" value-date="2016-11-28">52895</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-11-28"></transaction-date>
   <value currency="EUR" value-date="2016-11-28">52895</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-03-27"></transaction-date>
   <value currency="EUR" value-date="2018-03-27">52895</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-03-28"></transaction-date>
   <value currency="EUR" value-date="2018-03-28">52895</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-03-27"></transaction-date>
   <value currency="EUR" value-date="2019-03-27">52895</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-03-28"></transaction-date>
   <value currency="EUR" value-date="2019-03-28">52895</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-07-20"></transaction-date>
   <value currency="EUR" value-date="2021-07-20">105785</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-07-21"></transaction-date>
   <value currency="EUR" value-date="2021-07-21">105785</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <related-activity ref="NL-KVK-41207989-P-10706-2S4KN" type="1"></related-activity>
 </iati-activity>
</iati-activities>
